Analyzing AxoGen (NASDAQ:AXGN) & Solventum (NYSE:SOLV)

Solventum (NYSE:SOLV) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Solventum and AxoGen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1	3	10	0	2.64
AxoGen	1	2	13	0	2.75

Solventum currently has a consensus target price of $87.55, suggesting a potential upside of 0.73%. AxoGen has a consensus target price of $57.92, suggesting a potential upside of 18.80%. Given AxoGen’s stronger consensus rating and higher probable upside, analysts plainly believe AxoGen is more favorable than Solventum.

Institutional & Insider Ownership

80.3% of AxoGen shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Solventum and AxoGen”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.32 billion	1.78	$1.56 billion	$8.18	10.63
AxoGen	$225.21 million	12.93	-$15.70 million	($0.65)	-75.00

Solventum has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Solventum and AxoGen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solventum	17.26%	25.09%	8.78%
AxoGen	-11.96%	-5.35%	-4.41%

Volatility and Risk

Solventum has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

About AxoGen

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.